Trials / Completed
CompletedNCT00127478
A Long Term Safety Study With Atrasentan
A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan |
Timeline
- Start date
- 2001-07-01
- Completion
- 2007-06-01
- First posted
- 2005-08-08
- Last updated
- 2007-11-29
Locations
15 sites across 5 countries: United States, Canada, France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00127478. Inclusion in this directory is not an endorsement.